NCT00703833
Completed
Phase 2
A Double-Blind, Multicenter, Placebo-Controlled Study of MK0777 Gel Extrusion Module (GEM) 1.5 mg b.i.d. in the Treatment of Outpatients With Generalized Anxiety Disorder
ConditionsGeneralized Anxiety Disorder
Overview
- Phase
- Phase 2
- Intervention
- MK0777
- Conditions
- Generalized Anxiety Disorder
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 51
- Primary Endpoint
- Measure the reduction of anxiety
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The study will look at the effectiveness of MK0777 in patients with Generalized Anxiety Disorder.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or Female
- •Current diagnosis of Generalized Anxiety Disorder
- •Age 18 - 70
Exclusion Criteria
- •Women who are pregnant, or breast-feeding
- •Use of illicit drugs
- •History of drug or alcohol dependence
Arms & Interventions
1
Drug
Intervention: MK0777
2
Placebo
Intervention: Placebo (unspecified)
Outcomes
Primary Outcomes
Measure the reduction of anxiety
Time Frame: after 4 weeks and at end of study
Secondary Outcomes
- Safety and efficacy(throughout study and at end of study)
Similar Trials
Completed
Phase 4
A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety DisorderAnxiety Disorders,Generalized Anxiety DisorderNCT03924323AbbVie273
Completed
Phase 2
A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)Anxiety DisordersNCT00543920Merck Sharp & Dohme LLC60
Completed
Phase 2
Treatment of Patients With Anxiety Disorder (0777-022)Generalized Anxiety DisorderNCT00539578Merck Sharp & Dohme LLC270
Completed
Phase 3
Experimental Medication For the Treatment of Generalized Anxiety DisorderAnxiety DisorderNCT00097708Jazz Pharmaceuticals511
Completed
Phase 2
Combined Treatment for Generalized Anxiety Disorder (GAD)Generalized Anxiety DisorderNCT00620776University of Pennsylvania69